Year-end Sale % OFF 
Abstract
The goal of this study was to develop and characterize Angiopep-2 attached PEGylated Polypropylene imine (PPI) dendrimers for Temozolomide administration to brain gliomas. For surface neutralisation, synthesized PPI dendrimers were conjugated with PEG-2000. PEGylated PPI dendrimers were further coupled with Angiopep-2 (ANG-PEG-PPP) for enhanced medication transport across the blood-brain barrier (BBB) into the area of the brain tumour. Temozolomide loaded ligand-conjugated PPI dendrimers (TAPP) were characterized for size, % drug loading, cumulative drug release, and cell line studies. The drug loading was found to be 57.42±0.8%. In vitro release profile exhibited an early burst release followed by zero-order kinetics (46.8±0.8% in 24 hours). TAPP dendrimers showed improved antiproliferative efficacy against C6 glioma cells in MTT assays and cellular uptake investigations. The ability of TAPP to target cancer cells was examined using an in vitro co-culture model of BCECs and C6 glioma cells. Our findings suggest that Angiopep-2 coupled PEGylated PPI dendrimers could be a suitable nanocarrier for Temozolomide delivery to brain gliomas.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Medical pharmaceutical and allied sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
